avanafil indications/contra

Stem definitionDrug idCAS RN
inhibitors of phosphodiesterase PDE5 with vasodilator action 4305 330784-47-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • spedra
  • TA 1790
  • stendra
  • avanafil
a selective inhibitor of cGMP-specific PDE5 has no direct relaxant effect on isolated human corpus cavernosum, but enhances the effect of NO by inhibiting PDE5, which is responsible for degradation of cGMP in the corpus cavernosum
  • Molecular weight: 483.96
  • Formula: C23H26ClN7O3
  • CLOGP: 2.36
  • LIPINSKI: 0
  • HAC: 10
  • HDO: 3
  • TPSA: 125.39
  • ALOGS: -4.21
  • ROTB: 9

Drug dosage:

DoseUnitRoute
0.10 g O

Approvals:

DateAgencyCompanyOrphan
June 21, 2013 EMA
April 27, 2012 FDA VIVUS

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 73.08 60.21 20 28 116070 3269741

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC G04BE10 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs used in erectile dysfunction
CHEBI has role CHEBI:35620 vasodilator agent
FDA EPC N0000175599 Phosphodiesterase 5 Inhibitor
FDA MoA N0000020026 Phosphodiesterase 5 Inhibitors

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Impotence indication 397803000

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.01 acidic
pKa2 4.93 Basic
pKa3 3.61 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG STENDRA METUCHEN PHARMS N202276 April 27, 2012 RX TABLET ORAL 6656935 April 27, 2025 TREATMENT OF ERECTILE DYSFUNCTION
200MG STENDRA METUCHEN PHARMS N202276 April 27, 2012 RX TABLET ORAL 6656935 April 27, 2025 TREATMENT OF ERECTILE DYSFUNCTION
50MG STENDRA METUCHEN PHARMS N202276 April 27, 2012 RX TABLET ORAL 6656935 April 27, 2025 TREATMENT OF ERECTILE DYSFUNCTION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
cGMP-specific 3',5'-cyclic phosphodiesterase Enzyme INHIBITOR IC50 8.28 WOMBAT-PK CHEMBL
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha' Enzyme IC50 6.20 WOMBAT-PK
cGMP-specific 3',5'-cyclic phosphodiesterase Enzyme IC50 8.28 CHEMBL

External reference:

scroll-->
IDSource
C3473125 UMLSCUI
7448 IUPHAR_LIGAND_ID
D03217 KEGG_DRUG
DR5S136IVO UNII
8572 INN_ID
C553414 MESH_SUPPLEMENTAL_RECORD_UI
DB06237 DRUGBANK_ID
CHEMBL1963681 ChEMBL_ID
1291301 RXNORM
28514 MMSL
d07863 MMSL
015259 NDDF
4032978 VANDF
N0000189941 NDFRT
703956007 SNOMEDCT_US
703957003 SNOMEDCT_US
9869929 PUBCHEM_CID
CHEBI:66876 CHEBI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Stendra HUMAN PRESCRIPTION DRUG LABEL 1 76299-320 TABLET 50 mg ORAL NDA 17 sections
Stendra HUMAN PRESCRIPTION DRUG LABEL 1 76299-321 TABLET 100 mg ORAL NDA 17 sections
Stendra HUMAN PRESCRIPTION DRUG LABEL 1 76299-322 TABLET 200 mg ORAL NDA 17 sections